Using the LSC detection method validated in AML, we characterized aberrant marker expressions on CD34+CD38− cells and defined aberrant maker-positive CD34+CD38− cells as IA-HSCs (SI: Gating strategy of IA-HSCs) [19, 36]. This evidence concerns the gene CD34 and acute myeloid leukemia.